Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Endosomal TLRs play an important role in innate immune response as well as in autoimmune processes. In the therapy of systemic lupus erythematosus, antimalarial drugs chloroquine, hydroxychloroquine, and quinacrine have been used for a long time. Their suppression of endosomal TLR activation has been attributed to the inhibition of endosomal acidification, which is a prerequisite for the activation of these receptors. We discovered that chloroquine inhibits only activation of endosomal TLRs by nucleic acids, whereas it augments activation of TLR8 by a small synthetic compound, R848. We detected direct binding of antimalarials to nucleic acids by spectroscopic experiments and determined their cellular colocalization. Further analysis revealed that other nucleic acid-binding compounds, such as propidium iodide, also inhibited activation of endosomal TLRs and colocalized with nucleic acids to endosomes. We found that imidazoquinolines, which are TLR7/8 agonists, inhibit TLR9 and TLR3 even in the absence of TLR7 or TLR8, and their mechanism of inhibition is similar to the antimalarials. In contrast to bafilomycin, none of the tested antimalarials and imidazoquinolines inhibited endosomal proteolysis or increased the endosomal pH, confirming that inhibition of pH acidification is not the underlying cause of inhibition. We conclude that the direct binding of inhibitors to nucleic acids mask their TLR-binding epitope and may explain the efficiency of those compounds in the treatment…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In phagocytic cells, the deacidification of endosomes using pharmacological inhibitors like chloroquine has been shown to reduce endosomal toll-like receptor (TLR) response (de Bouteiller et al., 2005; Fox, 2019; Kuznik et al., 2011; Wozniacka et al., 2006; Yang et al., 2016)”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Kuznik et al., 2011
In the citing paper
“Hydroxychloroquine (HCQ) is an approved anti-malaria drug, and accumulation of hydroxychloroquine inhibits the binding ability of TLR9 to DNA and subsequent immune activation (77).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [77]
Citations
Cites
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
ACIDIFICATION OF THE ENDOCYTIC AND EXOCYTIC PATHWAYS
Mellman, I., Fuchs, R., & Helenius, A. (1986) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.55.070186.003311 · Cited by 2,032
Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J., & Marshak-Rothstein, A. (2002) · Nature · doi:10.1038/416603a · Cited by 1,900
Yoshimori, T., Yamamoto, A., Moriyama, Y., Futai, M., & Tashiro, Y. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47429-2 · Cited by 1,328
Toll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116
Barrat, F. J., Meeker, T., Gregorio, J., Chan, J. H., Uematsu, S., Akira, S., Chang, B., Duramad, O., & Coffman, R. L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050914 · Cited by 928
Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9
Means, T. K., Latz, E., Hayashi, F., Murali, M. R., Golenbock, D. T., & Luster, A. D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523025 · Cited by 849
Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8
Gorden, K. B., Gorski, K. S., Gibson, S. J., Kedl, R. M., Kieper, W. C., Qiu, X., Tomai, M. A., Alkan, S. S., & Vasilakos, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1259 · Cited by 683
Häcker, H., Mischak, H., Miethke, T., Liptay, S., Schmid, R., Sparwasser, T., Heeg, K., Lipford, G. B., & Wagner, H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.21.6230 · Cited by 653
The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor
Ewald, S. E., Lee, B. L., Lau, L., Wickliffe, K. E., Shi, G.-P., Chapman, H. A., & Barton, G. M. (2008) · Nature · doi:10.1038/nature07405 · Cited by 617
Research works printed but not linked: 2
- Ahmad-Nejad, 2002, Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments, Eur. J. Immunol., 32, 1958, 10.1002/1521-4141(200207)32:7<1958::aid-immu1958>3.0.co;2-u · DOI · Paper page
- Peacocke, 1973, Acridines, 723
Cited by
Items 601–627 of 627
Systematic Study of OX40 Ligand Context-Dependent Function on Human T Helper Cell Polarization
Karpf, L. (2020) · theses.fr (ABES) · doi:10.70675/b19ae5a1z0ff8z4de6zb2bczca89c6e7a7da
Ferrière, A. (2022) · theses.fr (ABES) · doi:10.70675/967bac29z3e09z4a95z9f5ezdafb2b6bf2ea
Belkacem, I. A. (2022) · theses.fr (ABES) · doi:10.70675/8c91113fz9692z44e4za5f4z5375d5ee8169
TLR mediated inflammatory disease and other type I interferonopathies
David, C. (2024) · theses.fr (ABES) · doi:10.70675/a5480faaz9003z4495z9b90z52963b0dbffc · Cited by 1
Étude de la fonction de la DNASE1L3 en contexte auto-immun et anti-tumoral
Santa, P. (2024) · theses.fr (ABES) · doi:10.70675/2af1f0cfz45caz418azb93ez88367c4a54c8
Demirağ, A. D., Aksoy, R. A., Akman, G., Kaya, V., & Yıldırım, M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0347956
Gene therapy development for retinal diseases
Reichel, F. F., Bellingrath, J.-S., Király, P., & FISCHER, M. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00016-1
Jefferies, C. A., Bose, M., & Kumar, A. N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33957-8.00017-2
The antimalarials in the treatment of lupus
Liossis, S. C., & Staveri, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33957-8.00064-0
Aflaki, M., & Bargman, J. M. (2026) · Frontiers in Lupus · doi:10.3389/flupu.2026.1725054
A, A. K. K., Hanna Tri Indah Farras, S., Nazar, R., Sathya, M., Venkateswaran, R., Karthikeyan, V., & Pavithran, V. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04154-z
Thomas, L., Laffitte, E., Lenormand, C., & Pham, F. (2026) · Elsevier eBooks · doi:10.1016/b978-2-294-77608-3.00155-1
Zhao, S., Jiang, H., Yan, Y., & Wu, R. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08357-8
miR-26a-5p Activates Antiviral Innate Immunity via Direct Binding and Activation of RIG-I
Xiong, J., Lin, X., Tang, W., Wu, L., Chen, Q., Li, M., Huang, X., Zhao, L., & Chen, S. (2026) · Viruses · doi:10.3390/v18091005
Lainšček, D., Malenšek, Š., Forstnerič, V., Golob-Urbanc, A., Orehek, S., Bohinc, J., Keber, M. M., Sotošek, T., Esih, H., Pečan, P., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.09.033
Self-citationAssociation of serum levels of galectin-9 and IP-10 with disease activation in lupus nephritis
Varelci, S., Çınar, S., Gürel, E., Mirioğlu, Ş., Uludağ, Ö., Torun, E. S., Yalçınkaya, Y., Gül, A., İnanç, M., & Artım-Esen, B. (2026) · Lupus · doi:10.1177/09612033261493837
Manz, J., Woernle, J., Hubbuch, J., Deepak, R., Noack, F., & Huellen, F. (2026) · Viruses · doi:10.3390/v18101158
BindingDB (2021) · UC San Diego · doi:10.7270/q2bp064w
BindingDB (2013) · UC San Diego · doi:10.7270/q2vh5pvx
BindingDB Entry 50034406: Potent adjuvantic activity of a CCR1-agonistic bis-quinoline.
BindingDB (2012) · UC San Diego · doi:10.7270/q2dz08r5
BindingDB (2023) · UC San Diego · doi:10.7270/q2w66qpp
Abe, F., Saito, M., Saito, A., Hashimoto, M., Kanazawa, T., Kumagai, T., Sakaguchi, M., Ishii, F., Wakui, H., & Takahashi, N. (2026) · Lupus · doi:10.1177/09612033261505701
Metadata
- Authors
- Kužnik, A., Benčina, M., Švajger, U., Jeras, M., Rozman, B., & Jerala, R.
- Affiliations
- National Institute of Chemistry (SI)
- Blood Transfusion Centre of Slovenia (SI)
- Ljubljana University Medical Centre (SI)
- University of Ljubljana (SI)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04
- Volume
- 186
- Issue
- 8
- Pages
- 4794-4804
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2118400571
- Cited by
- 606
- References
- 40
- Citations by year
- 2026: 21 · 2025: 24 · 2024: 43 · 2023: 30 · 2022: 42 · 2021: 69 · 2020: 89 · 2019: 38 · 2018: 39 · 2017: 38 · 2016: 41 · 2015: 43 · 2014: 32 · 2013: 22 · 2012: 28
- FWCI
- 12.77
- Type
- journal article
- Language
- en
- Open access
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Repository of the University of Ljubljana (University of Ljubljana) (publishedVersion, other-oa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- antimalarial drugs, imidazoquinolines, chloroquine, hydroxychloroquine, quinacrine, TLR8, R848, nucleic acid binding, endosomal acidification, TLR9, TLR3, TLR7/8 agonist, systemic lupus erythematosus, autoimmune disease therapy, propidium iodide, bafilomycin
- MeSH terms
- Animals, Antimalarials, Binding, Competitive, Cell Line, Cells, Cultured, Chloroquine, Culture Media, Humans, Hydrogen-Ion Concentration, Imidazoles, Nucleic Acids, Quinacrine, Quinolines, Endosomes, Transfection, Cytokines, Serum, Toll-Like Receptors, Toll-Like Receptor 3, Toll-Like Receptor 7, Toll-Like Receptor 8, Toll-Like Receptor 9, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.